Analysts Set Expectations for Fractyl Health FY2028 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS) – HC Wainwright boosted their FY2028 earnings estimates for shares of Fractyl Health in a report released on Tuesday, August 11th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $0.03 for the year, up from their prior estimate of $0.02. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Fractyl Health’s FY2029 earnings at $0.38 EPS and FY2030 earnings at $0.95 EPS.

Several other research analysts have also weighed in on the company. Craig Hallum assumed coverage on Fractyl Health in a research report on Wednesday, July 1st. They set a “buy” rating and a $4.00 price target on the stock. Weiss Ratings lowered Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.12.

Fractyl Health Price Performance

GUTS opened at $0.70 on Wednesday. The firm has a market capitalization of $111.34 million, a P/E ratio of -0.80 and a beta of 2.32. The stock has a fifty day moving average of $0.76 and a 200-day moving average of $0.69. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 1.41. Fractyl Health has a 12-month low of $0.38 and a 12-month high of $2.44.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02.

Insider Buying and Selling

In related news, Director William Bradley bought 68,493 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was bought at an average price of $0.73 per share, with a total value of $49,999.89. Following the purchase, the director directly owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. This represents a 424.66% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Ian Sheffield bought 35,000 shares of the firm’s stock in a transaction on Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, with a total value of $25,550.00. Following the purchase, the director directly owned 35,000 shares in the company, valued at approximately $25,550. This trade represents a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 171,493 shares of company stock valued at $127,150. Insiders own 8.52% of the company’s stock.

Institutional Trading of Fractyl Health

A number of institutional investors have recently bought and sold shares of GUTS. Nantahala Capital Management LLC acquired a new position in Fractyl Health in the 3rd quarter worth about $19,298,000. Alyeska Investment Group L.P. acquired a new stake in shares of Fractyl Health during the 3rd quarter valued at about $8,981,000. Woodline Partners LP lifted its holdings in shares of Fractyl Health by 821.1% during the 3rd quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock valued at $8,755,000 after buying an additional 4,908,693 shares during the last quarter. General Catalyst Group Management LLC acquired a new stake in shares of Fractyl Health during the 2nd quarter valued at about $7,912,000. Finally, Marshall Wace LLP grew its stake in shares of Fractyl Health by 234.9% in the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock valued at $13,039,000 after buying an additional 4,156,969 shares in the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.